Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Cure8 research brief
Why This Matters
For people with Crohn’s disease, this study suggests that biologic drugs reduce inflammation in both proximal and distal small bowel to a similar degree, as measured by capsule endoscopy.
That matters because proximal small-bowel disease has been linked with worse outcomes, so similar healing across regions is reassuring for overall small-bowel response to biologics.
Who Should Pay Attention
Adult patients with small-bowel Crohn’s disease, patients starting or optimizing biologic therapy, gastroenterologists, and researchers studying mucosal healing or small-bowel imaging.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This pooled analysis of three prospective cohorts used small-bowel video capsule endoscopy (SB-VCE) to compare mucosal inflammation in proximal versus distal small bowel segments among patients with Crohn’s disease starting or optimizing biologic therapy.
Ninety-nine patients (majority on anti-TNF or vedolizumab; three on ustekinumab) had baseline and follow-up VCE at end-of-induction (14–26 weeks) and 1 year.
The study defined mucosal inflammation by Lewis score thresholds and found that biologic therapy reduced inflammation in both proximal and distal small bowel, with no statistically significant difference in the degree of mucosal healing between the two regions at either follow-up timepoint.
Key details from the report are grounded in the article abstract and include cohort size, timing of VCE assessments, Lewis score thresholds used to define inflammation, and the main comparative finding (topographically comparable improvement).
If you want the original study details (methods, full statistics, or subgroup analyses) consult the full journal article on PubMed or the journal site for complete tables and methods.
Keep In Mind
Structured content depth: abstract — the curator note summarizes the study abstract provided on PubMed. The brief is based on the abstract text; consult the full paper for complete methods, statistical details, and subgroup analyses. Lewis score thresholds and VCE interpretation are specialized measures; discuss individual implications with your clinician.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
AuthorsOffir Ukashi, Uri Kopylov, Bella Ungar +9 more
InstitutionGastroenterology Institute, Sheba Medical Center Tel Hashomer, Ramat Gan, and the Gray School of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel. Electronic address: offirukashi@gmail.com.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 5, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Multimodal monitoring of pan-enteric mucosal healing and biologic persistence in Crohn's disease-the MILESTONE-CD prospective cohort.
Measuring mucosal healing across the whole gut with stool markers, ultrasound, and capsule endoscopy may give a clearer picture of whether biologic treatment is working and help guide decisions about continuing or...
Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
The study suggests active smoking reduces the effectiveness of anti-TNF biologics in people with IBD, which could affect treatment response and the need to switch or escalate therapies. This supports including smoking...
Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...